Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms

The blockbuster weight-loss drugs reshaping modern medicine may have a second act in one of gastroenterology’s most stubborn diseases. A new narrative review published in Frontiers in Gastroenterology on 21 August 2026 suggests that glucagon-like peptide-1 receptor agonists, the drug class behind semaglutide and tirzepatide, can safely help patients with inflammatory bowel disease lose weight, improve metabolic control, and possibly dampen the inflammation that drives Crohn’s disease and ulcerative colitis. The review, led by researchers at Thomas Jefferson University Hospital in Philadelphia, arrives as obesity among patients with inflammatory bowel disease continues to climb, with estimates now ranging from 15 to 40 percent of this population.

That rising prevalence matters for reasons that go far beyond body weight. Obesity has been linked to a more severe course of inflammatory bowel disease, including lower rates of corticosteroid-free remission, increased risk of surgery among patients receiving anti-tumor necrosis factor alpha therapy, biologic treatment failure, and shorter intervals between disease flares. It may also help explain a persistent therapeutic gap: 40 to 60 percent of patients with Crohn’s disease and ulcerative colitis fail to respond to advanced therapies. One proposed culprit is the hormonally active visceral fat packed around the intestines. A multi-center prospective study found that patients with greater intra-abdominal visceral adipose tissue were less likely to achieve corticosteroid-free or endoscopic remission when starting biologic therapy. Crohn’s patients who did not respond to biologics had higher visceral fat levels than responders, and those non-responders with elevated visceral fat also carried increased serum levels of the inflammatory signaling molecules interleukin-6 and tumor necrosis factor alpha.

Against that backdrop, the Jefferson team set out to evaluate the safety and clinical effectiveness of GLP-1 receptor agonists in patients with inflammatory bowel disease, and to summarize the theorized anti-inflammatory mechanisms that could make these metabolic drugs useful beyond weight loss alone. Because the existing literature is heterogeneous in interventions and outcomes, the authors chose a narrative review rather than a systematic one. They searched PubMed through July 2026 using index terms combining GLP-1 receptor agonists with inflammatory bowel disease, Crohn’s disease, and ulcerative colitis alongside safety, effectiveness, and outcomes. The initial search yielded 187 results, expanded through forward and backward citation chaining. Studies focused on GLP-2 analogs, short bowel syndrome, DPP-4 inhibitors, or microbiota effects on the GLP-1 axis were excluded, and preprint data was omitted. Two reviewers extracted data independently, resolving discrepancies through discussion.

The weight loss findings were strikingly consistent. In an 18-month analysis, patients with inflammatory bowel disease taking semaglutide lost a mean of 16 pounds, statistically indistinguishable from the 18 pounds lost by a non-IBD control cohort. In case series, 58.3 percent of patients achieved at least 5 percent weight reduction at six months, while another cohort reported a significant drop in mean body mass index from 34 to 31 kilograms per square meter alongside a median total body weight loss of 8.15 kilograms. Clarke and colleagues reported that 64.7 percent of IBD patients achieved at least 5 percent weight loss and 46.1 percent achieved 10 percent within one year. Systematic reviews of retrospective cohort studies confirmed significant body weight reductions. Which specific agent works best remains contested: one study found semaglutide associated with the greatest weight loss at 12 to 24 weeks, while another reported tirzepatide outperformed semaglutide, highlighting the need for head-to-head prospective trials.

Metabolic outcomes were more modest and less consistent. In a subgroup of patients with inflammatory bowel disease and type 2 diabetes, GLP-1 receptor agonists produced a modest 0.3 percent reduction in hemoglobin A1c at six months, though one cohort study found no significant difference in A1c or total cholesterol, and a systematic review noted inconsistent effects on HDL, triglycerides, LDL, and total cholesterol. The safety profile, however, emerged as largely reassuring. Gastrointestinal adverse effects, chiefly nausea, vomiting, and diarrhea, were the most frequently reported problems and often limited treatment continuity. One retrospective cohort found 11 percent of IBD patients on GLP-1 therapy experienced these symptoms, and of 25 patients who had side effects, 23 discontinued therapy. Another cohort found 24 percent stopped the drugs, with roughly half citing gastrointestinal intolerance. Yet a study of 271 patients comparing pre- and post-treatment periods found no significant difference in gastrointestinal adverse events, calling into question whether the symptoms were truly drug-related.

More serious concerns appear largely unfounded. Although ileus, a potentially dangerous halt in intestinal movement, has been raised as a theoretical risk in the general population, a Danish nationwide cohort study of 61,927 patients with inflammatory bowel disease found that GLP-1 receptor agonists were not associated with increased risk of ileus or intestinal obstruction. In a retrospective study of 272 IBD patients, only 7 percent of reported adverse effects were non-gastrointestinal, and no serious adverse events occurred. Hypoglycemia, injection site reactions, and death each occurred in 1.1 percent of cases in another study, rates comparable to non-IBD populations. No differences or reduced risk were observed in gallbladder disease, pancreatitis, or acute kidney injury compared to IBD patients not taking the drugs.

The effects on inflammatory biomarkers told a more nuanced story. One retrospective study reported a significant reduction in C-reactive protein from 9.0 to 1.6 milligrams per deciliter at 12 to 24 weeks after initiation, independent of any change to IBD therapy, though a smaller study of 36 patients found no significant CRP difference. Fecal calprotectin, a stool marker of intestinal inflammation, showed no consistent change across studies. On clinical outcomes, the evidence was mixed but not alarming. Large-scale studies found GLP-1 therapy associated with a significant reduction in a composite outcome of steroid-dependence, advanced therapy initiation, IBD-related surgery, and hospitalization, along with decreased risk of recurrent pouchitis. Notably, these improved outcomes were not seen in individuals without obesity. Conversely, several studies found no difference in steroid use, hospitalization, medication changes, or surgeries after one year of therapy, and two of 26 patients in one Spanish study clinically worsened. Surgical outcomes appeared favorable, with reduced colectomy rates in ulcerative colitis and lower likelihood of abdominal surgery in Crohn’s disease, with semaglutide the only agent to significantly reduce IBD-related surgery risk in Crohn’s patients. Endoscopic data remains sparse, though one case report described a Mayo score dropping from 5 to 2 after 25 years of active disease on liraglutide.

Beneath the clinical findings lies a web of proposed molecular mechanisms. GLP-1 receptor agonists may inhibit the AKT/NF-κB signaling pathway, a transcriptional hub that regulates proinflammatory cytokines including tumor necrosis factor alpha, interleukin-6, interleukin-1 beta, and COX-2, all implicated in the intestinal barrier disruption seen in Crohn’s disease and ulcerative colitis. The drugs may also reduce recruitment of inflammatory cells by inhibiting chemokine production from colonic smooth muscle cells. Additional mechanisms include maintenance of regulatory T cell levels that counteract proinflammatory Th17 cells, expansion of group 3 innate lymphoid cells that regulate intestinal immunity, upregulation of barrier-protective genes such as IL-33, CCL20, and MUC5B, promotion of anti-inflammatory cytokines like IL-10, protection against reactive oxygen species, and increased signaling through the AMPK pathway. The authors caution that most of these mechanisms have been identified in non-human models, and their translational relevance in patients remains to be established.

The review also offers practical prescribing guidance. Clinicians should establish baseline disease activity before initiation, using inflammatory biomarkers or endoscopic evaluation, so that new-onset diarrhea or abdominal pain can be properly differentiated between drug side effects and a genuine flare. Persistent upper gastrointestinal symptoms with normal inflammatory markers may warrant upper endoscopy and gastric emptying studies, while lifestyle modifications such as smaller, more frequent meals and avoiding spicy or high-fat foods can help manage symptoms. Starting at the lowest possible dose with slow titration is recommended, and switching to an alternate agent within the class may help patients who cannot tolerate a particular drug. Immediate discontinuation is reserved for confirmed acute pancreatitis without other etiology, new hepatobiliary pathology, and the drugs remain contraindicated in patients with a family history of medullary thyroid cancer or MEN syndrome type 2. Women of reproductive age should use contraception given unknown pregnancy safety.

The authors acknowledge significant limitations: the retrospective nature of existing studies, small sample sizes, heterogeneity in agents and dosages, and the absence of prospective randomized controlled trials to establish causal effects. Still, the overall message is cautiously optimistic. GLP-1 receptor agonists have not been associated with worsening of inflammatory bowel disease across multiple studies, and there is emerging evidence of benefit in systemic inflammation and some clinical outcomes. As obesity becomes an increasingly recognized modifiable factor in IBD management, these metabolic drugs may prove to be more than weight-loss tools, potentially serving as adjuvant therapy that addresses the inflammatory burden carried by hormonally active visceral fat. Longitudinal studies will be required to clarify their long-term impact on clinical and endoscopic outcomes, but for now, the convergence of two of medicine’s biggest stories, the GLP-1 revolution and the quest to tame inflammatory bowel disease, offers a compelling new frontier for patients and clinicians alike.

Subject of Research: GLP-1 receptor agonists show promise for patients with inflammatory bowel disease and obesity

Article Title: Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms

Article References: Fernando, S., Zhao, J., Josloff, K., Zubair, N., Desai, A., Shivashankar, R., Kozuch, P. L., Choudhary, C., Lichtenstein, G., & Sehgal, P. (2026). Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms. Frontiers in Gastroenterology, 5, Article 1864456. https://doi.org/10.3389/fgstr.2026.1864456

Image Credits: AI Generated

DOI: 10.3389/fgstr.2026.1864456

Keywords: Glucagon, like, peptide, receptor, agonists, patients, inflammatory, bowel, disease, safety, clinical, effectiveness